ibudilast has been researched along with Allergic Encephalomyelitis in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 5.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 1.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| "Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood." | 1.48 | Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline. ( Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sharifian, A | 1 |
| Varshosaz, J | 1 |
| Aliomrani, M | 1 |
| Kazemi, M | 1 |
| Fujita, M | 1 |
| Tamano, R | 1 |
| Yoneda, S | 1 |
| Omachi, S | 1 |
| Yogo, E | 1 |
| Rokushima, M | 1 |
| Shinohara, S | 1 |
| Sakaguchi, G | 1 |
| Hasegawa, M | 1 |
| Asaki, T | 1 |
| Fujimoto, T | 1 |
| Sakoda, S | 1 |
| Fujimura, H | 1 |
| Yanagihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ibudilast and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model.
Topics: Animals; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Mice, Inb | 2023 |
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Hyperalgesia; Injections, Spin | 2018 |
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Topics: Administration, Oral; Animals; Cell Division; Disease Models, Animal; Encephalomyelitis, Autoimmune, | 1999 |